Clinical Trials Logo

Clinical Trial Summary

The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.

The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib activity and establishing a cutoff value as potential selection criteria for phase III.

Other secondary objectives are to assess the tolerability and safety of lenvatinib in this setting and overall survival, response and disease control.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT03005015
Study type Interventional
Source European Organisation for Research and Treatment of Cancer - EORTC
Status Withdrawn
Phase Phase 2
Start date January 2017

See also
  Status Clinical Trial Phase
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Recruiting NCT03291106 - Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
Completed NCT00341458 - Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
Recruiting NCT04865289 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Phase 3
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT01460979 - Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Enrolling by invitation NCT03935282 - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors N/A
Completed NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase 2
Recruiting NCT03766672 - Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique
Recruiting NCT01820884 - The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma N/A
Recruiting NCT01820858 - The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Phase 3
Active, not recruiting NCT03276013 - Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer Phase 2
Recruiting NCT04269200 - Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer Phase 3
Completed NCT02387645 - LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma N/A
Recruiting NCT03570437 - Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Phase 2
Not yet recruiting NCT01178736 - Early Detection of Cancers in Low Resource Countries Phase 0